Not So Different: How Henlius is Making Its Mark on the Global Biosimilar Industry

Jun 20, 11:00 AM

Ping Cao, vice president of Business Development for Shanghai Henlius Biotech, discussed the company's current biosimilar development plans and the process for getting regulatory approval for biosimilars in China.

To hear more comments from Ping Cao, click here.
To learn more about Henlius’ development plans, click here.
To learn more about Henlius’ approval for their adalimumab biosimilar, click here.
To learn more about PD-1 inhibitors, click here.